Reevaluation of predictive biomarkers of diffuse large B-cell lymphoma in the rituximab era

范艳兰; 李小秋

doi:10.3969/j.issn.1007-3969.2013.06.012

您当前的位置：

首页 >

文章列表页 >

Reevaluation of predictive biomarkers of diffuse large B-cell lymphoma in the rituximab era

更新时间：2025-12-31

- Reevaluation of predictive biomarkers of diffuse large B-cell lymphoma in the rituximab era
- China Oncology Vol. 23, Issue 6, Pages: 467-471(2013)
- 作者机构：
  
  复旦大学附属肿瘤医院病理科，复旦大学上海医学院肿瘤学系,上海,200032
- 作者简介：
- 基金信息：
- DOI：10.3969/j.issn.1007-3969.2013.06.012
  CLC：
- Published Online：13 November 2014，
  
  Published：2013
- 稿件说明：
移动端阅览
范艳兰,李小秋. 应用利妥昔单抗治疗弥漫性大B细胞淋巴瘤预后相关标志物的再评估[J]. 中国癌症杂志, 2013, 23(6): 467-471.

范艳兰, 李小秋. Reevaluation of predictive biomarkers of diffuse large B-cell lymphoma in the rituximab era[J]. China Oncology, 2013, 23(6): 467-471.
范艳兰,李小秋. 应用利妥昔单抗治疗弥漫性大B细胞淋巴瘤预后相关标志物的再评估[J]. 中国癌症杂志, 2013, 23(6): 467-471. DOI： 10.3969/j.issn.1007-3969.2013.06.012.

范艳兰, 李小秋. Reevaluation of predictive biomarkers of diffuse large B-cell lymphoma in the rituximab era[J]. China Oncology, 2013, 23(6): 467-471. DOI： 10.3969/j.issn.1007-3969.2013.06.012.

摘要

弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma

DLBCL)是一组在发病机制和细胞起源方面都具有异质性的肿瘤。早期的预后模型(如国际预后指数)着重强调年龄、临床分期、行为状态评分等临床因素对患者预后的影响，并未反映这类疾病生物学异质的特点。虽然曾有研究表明，某些分子标志物与该类肿瘤的预后存在明确相关性，但随着抗CD20的利妥昔单抗日益广泛的应用，DLBCL的治疗策略和疗效均发生了相应的变化。因此，在当前免疫化疗治疗模式下，有必要对DLBCL原有的预后相关分子指标予以重新评估。

Abstract

Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease in terms of molecular pathogenesis and cell of origin. Earlier prognostic models relied mainly on such clinical variables as age

stage of disease

and performance status

which did not display its heterogeneity. Many studies have reported that some biomarkers could be used for prognostication

while older prognostic models need to be revalidated and modified as improved therapeutic options become available. In this review

we discussed pertinent studies on individual biomarkers and pattern-based biomarker models

with an emphasis on markers evaluated in patients treated with rituximabcontaining chemotherapy.

关键词

Keywords

references

Views

3117

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

Clinicopathologic features of SMARCA4-deficient pulmonary malignant tumor with an emphasis on the prognosis

Treatment strategies and prognostic analysis of 87 patients with salivary duct carcinoma: a retrospective cohort study

Impact of radiation-induced lymphopenia on prognosis in patients with limited-stage small cell lung cancer: a cohort study

MITF expression in acral melanoma tissues and its association with clinical, pathological characteristics and prognosis

A cohort study of prognostic value of ¹⁸F-FDG PET/CT metabolic parameters in patients with diffuse large B-cell lymphoma treated with CAR-T

Related Author

CHANG Kesheng

SHAO Jin

ZHANG Qi

LIU Yifei

Ximei ZHANG

Yixuan ZHOU

Yan ZHAO

Xuan ZHOU

Related Institution

Department of Pathology, Wuxi Second People’s Hospital

Department of Pathology, Affiliated Hospital of Nantong University

Department of Radiation Oncology, Tianjin Medical University Cancer Institute and Hospital, National Clinical Research Center for Malignant Tumors

Tianjin Clinical Research Center for Malignant Tumors

Stomatological Clinical College of Tianjin Medical University

AI问答

⁰